Study Evaluating AGG-523 in Subjects With Osteoarthritis

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00427687
First received: January 25, 2007
Last updated: August 1, 2008
Last verified: August 2008
  Purpose

This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.


Condition Intervention Phase
Osteoarthritis
Drug: AGG-523
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • The effect of AGG-523 on biomarkers related to osteoarthritis.

Study Start Date: February 2007
Study Completion Date: June 2007
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion:

  • Mild to moderate Osteoarthritis of the target knee.
  • Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00427687

Locations
United States, California
Anaheim, California, United States, 92801
United States, Florida
Miami, Florida, United States, 33143
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16635
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00427687     History of Changes
Other Study ID Numbers: 3189A1-104
Study First Received: January 25, 2007
Last Updated: August 1, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on April 16, 2014